Cardinal Health announced a $5 billion equity buyback authorization on August 11, 2026. This is a repurchase program — it authorizes the company to buy back its own shares over time. No shares have necessarily been purchased yet.
For holders, buybacks reduce the share count outstanding, which can increase each remaining share's claim on earnings. For short sellers, the program is modest pressure: with short interest at 2.9% of free float and a cost to borrow of just 0.27%, the lending market is loose and the short position is small relative to the float.
Across 13 comparable buyback announcements among sector peers, shares moved an average of 2.14% over the following 5 trading days, with 69.2% of events moving in that direction.
See the live data behind this article on ORTEX.
Open CAH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
